On what date did the Onderstepoort Biological Products (OBP) last update the formulation of its African Horse Sickness (AHS) vaccine to ensure that its efficacy levels are maintained;
(2) (a) on what dates did OBP conduct efficacy and safety studies on its AHS vaccine (i) in each of the past five financial years and (ii) since 1 April 2021 and (b) what are the details of the outcomes of each efficacy and safety study in each case;
(3) whether she will furnish Mr J Engelbrecht with copies of the specified efficacy and safety studies; if not, why not; if so, what are the relevant details;
(4) what has she found to be the reasons for the delay in the approval of the applications in terms of section 20 of the Animal Diseases Act, Act 35 of 1984, for conducting efficacy and safety studies for experimental AHS vaccines already developed by other laboratories in the Republic?